Pharma BD Deal Intelligence
Theravance Biopharma and Mylan announced that they have entered into a development and commercialization agreement for TD-4208, a novel nebulized LAMA for the…
FDA accepted the NDA for revefenacin in adult COPD patients, with PDUFA action date set, marking on-time delivery of the partnership's regulatory milestone.
Theravance and Mylan expanded the Yupelri development and commercialization agreement to include China and adjacent territories, signaling continued partner…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Theravance Biopharma and Mylan partnered on development and commercialization of TD-4208 (revefenacin), a once-daily nebulized LAMA for COPD. Mylan paid $15M cash plus $30M equity investment at signing, with up to $220M in development/sales milestones. Mylan led US commercialization with Theravance co-promote rights; Mylan led ex-US (excluding China) development.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan Inc. / Theravance Biopharma, Inc. (TD-4208 program) (this deal) | 2015 | $265M | 61 |
| Mylan Inc. / Bioniche Pharma Holdings Limited | 2010 | $550M | 60 |
| Mylan Inc. / Famy Care Limited (women's healthcare businesses) | 2015 | $800M | 56 |
| Mylan Inc. / Agila Specialties (Strides Arcolab) | 2013 | $1.8B | 45 |
| Mylan Inc. / Abbott Laboratories (non-U.S. developed-markets specialty and branded generics business) | 2014 | $5.3B | 33 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Madison Dearborn Partners / Ikaria, Inc. | 2013 | $1.6B | 85 |
← Browse all deals · How we score deals
More: 2015 deals · Mylan Inc. deals · Respiratory deals